The analysis of the presence of KRAS mutations in tumor tissue in patients treated with EGFR-tyrosine kinase inhibitors (TKIs) was conducted in works of Pao et al. [47] and Massarelli et al. [48]. The gene discussed is EGFR; the disease is neoplasm.